Key Performance
More- Earnings Score: N/A
- Momentum Score: 68
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
LifeMD announced an exclusive co-marketing collaboration with Halozyme's subsidiary Antares Pharma to launch a direct-to-patient self-pay program for XYOSTED, an FDA-approved testosterone auto-injector. The program will launch in July 2026 across 37 states, offering patients virtual clinical evaluation, lab testing, and home delivery of medication at a transparent price of approximately $249 per month, addressing barriers to hypogonadism treatment.
06/22/2026, 8:00 AM • GlobeNewswire
Slash Your Wegovy Costs: Novo Nordisk Reveals First-Ever Subscription Plan
Novo Nordisk launched a subscription program for Wegovy (semaglutide) starting March 31, 2026, offering tiered pricing to reduce costs for self-pay patients. Monthly prices range from $329 to $249 for injections (up to $1,200 annual savings) and $289 to $249 for oral versions through telehealth partners including Ro, WeightWatchers, and LifeMD, with Hims & Hers and Sesame expected to join later. The program aims to improve treatment adherence and address cost barriers.
03/31/2026, 2:35 PM • Benzinga
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
LifeMD announced a quarterly cash dividend of $0.5546875 per share on its 8.875% Series A Cumulative Perpetual Preferred Stock, payable on April 15, 2026, to shareholders of record as of April 3, 2026.
03/24/2026, 4:05 PM • Benzinga
Novo Nordisk's Wegovy Weight Loss Pill Hits US Pharmacies With Lower Starting Cost
Novo Nordisk launched its Wegovy weight loss pill in US pharmacies in December 2025 with competitive pricing starting at $149/month for self-pay patients. The pill demonstrated 17% average weight loss versus 3% for placebo. It's available through major retailers including CVS and Costco, as well as telehealth providers. Despite the positive product launch, NVO stock remains down 35.61% over the past year and trades 8.4% below its 200-day moving average.
01/05/2026, 12:23 PM • Benzinga
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
LifeMD, Inc. announced a cash dividend of $0.5546875 per share for holders of its 8.875% Series A Cumulative Perpetual Preferred Stock, payable on January 15, 2026. The announcement reflects the company's financial stability as a leading virtual primary care provider.
12/26/2025, 8:00 AM • GlobeNewswire
Novo Nordisk Leans Into Affordability Amid Rising Competition
Novo Nordisk announced a price reduction for Wegovy and Ozempic, offering a $199/month introductory rate for new self-pay patients, and lowering the standard monthly price from $499 to $349 to improve medication accessibility.
11/17/2025, 1:01 PM • Benzinga
LifeMD announced lower cash-pay pricing for Wegovy and Ozempic medications at $199 per month, supporting patients paying out of pocket through its Weight Management Program in collaboration with Novo Nordisk.
11/17/2025, 8:00 AM • GlobeNewswire
Non-Sterile Compounding Pharmacy Market Size Expected to Reach USD 12.11 Bn by 2034
The global non-sterile compounding pharmacy market is projected to grow from $5.97 billion in 2024 to $12.11 billion by 2034, driven by increasing demand for personalized medications and growing chronic diseases, with North America currently leading the market.
10/27/2025, 11:00 AM • GlobeNewswire
The Schall Law Firm is pursuing a class action lawsuit against LifeMD for allegedly making false and misleading statements about its competitive position and financial guidance during May-August 2025.
10/27/2025, 3:02 AM • Benzinga
A class action lawsuit has been filed against LifeMD, alleging false statements about the company's competitive position and financial guidance for 2025, with potential securities law violations.
10/26/2025, 12:00 PM • GlobeNewswire
A class action lawsuit has been filed against LifeMD alleging false statements about the company's competitive position and financial guidance during May 7-August 5, 2025, with investors having until October 27th to apply as lead plaintiff.
10/26/2025, 10:17 AM • GlobeNewswire
Rosen Law Firm reminds LifeMD investors of an important October 27, 2025 deadline for a securities class action lawsuit, alleging the company made false or misleading statements about its competitive position and financial guidance.
10/26/2025, 9:45 AM • GlobeNewswire
Rosen Law Firm reminds LifeMD investors of an important October 27, 2025 deadline for a securities class action lawsuit, alleging the company made false or misleading statements about its competitive position and financial guidance.
10/26/2025, 9:45 AM • GlobeNewswire
A federal securities fraud lawsuit has been filed against LifeMD, alleging the telehealth company misled investors about its financial health and growth prospects during May-August 2025, resulting in a significant stock price decline.
10/25/2025, 2:49 PM • GlobeNewswire
Rosen Law Firm alerts LifeMD investors about a securities class action lawsuit alleging false statements about the company's competitive position and financial guidance during May 7-August 5, 2025.
10/18/2025, 12:35 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/23/2026
Company Profile
LifeMD, Inc. operates as a direct-to-patient telehealth company, engages in the provision of patients access to virtual medical care and pharmacy services in the United States. It offers telehealth platform comprising Rex MD, a men's telehealth platform that provides virtual diagnosis, treatment, and prescription medications for men's health conditions, including erectile dysfunction, premature ejaculation, hair loss, insomnia, weight loss, and performance anxiety; and ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss. The company also provides LifeMD PC, a virtual primary care and telehealth service which is a provider for their primary care, urgent care, and chronic care needs; and offers virtual medical care, including on-demand consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, integration with in-home tools, and more. In addition, it offers GLP-1 for weight management and in-home health monitoring devices. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.